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ABSTRACT : la expression and RNA content in BALF and peripheral blood were 
evaluated on the condition of combination therapy of Cyclosporine (CsA), Azathioprine 
(Azp), and Predonine (Pr) following lung allotransplanatation in dogs. 
1) la expression of lymphocytes in BALF was faciliated according to the appearance of 
rejection and depressed according to the disappearance of rejection. Thefore, it is indicated 
that la expression is one of the valuable monitorings to determine the appearance of 
rejection. 
2) The low RNA content of macrophages in BALF and monocytes in the peripheral blood 
showed regardless of the appearance of rejection or not. It was of no use to determine 
rejection on the condition of prescribing CsA.
       INTRODUCTION 
 Much progress has been made towards im-
provement of the result of lung transplanta-
tion according to prevalence of the use of CsA 
as an immunosuppressive drug. Therefore, the 
incidence of graft failure has become dimin-
ished. The major items of concern involve how 
to early and accurate detection for rejection of 
which histologic finding of bronchiolitis obliter-
ance is taken into consideration. It is accept-
ed that histologic finding from the specimen 
obtained by open lung biopsy, is valid to pre-
cisely make a diagnosis for rejection. How-
ever, it is necessary for detecting less invasive 
and less simple method than open lung biopsy". 
Nakano2' reported that positive rates of Ia-ex-
pression of lymphocytes in BALF are increased 
at rejection, and Itoh3' reviwed that RNA content 
of BALF macrophages increased with rejection. 
 The purpose of this study is to certify sig-
nificance of the measurement of la-expression 
and RNA content in macrophages and lympho-
cytes in BALF under the combination therapy 
of CsA, Azp and Pr to detect rejection at early 
stage of lung transplantation in dogs.
    MATERIAL AND METHOD 
1. Transplantation 
 Left lung allotransplants were performed in 
25 mongel dogs (each weighing 8 to 16kg). After 
the animals were anesthetized with intravenous 
administration of pentobarbiral (25mg/kg). The 
dogs were mechanically ventilated by Haverd 
ventilator through the tracheal tubes intubated 
orotracheally at a rate of 12 to 14/min, and a res-
piratory volume of 300 to 400ml. Left thoraco-
tomy at the fifth intcostal space was performed, 
and left lung in recipient was resected. After 
the left lung was dissected under heparinization, 
the graft was transplanted by anastomosing left 
atrium, pulmonary vein and bronchus of graft 
to recipient. 5-0 proline was used for anasto-
mosis to the to left atrium, 6-0 proline for 
plumonary. vein, and also 4-0 proline for bron-
chus. The ischemic time of the donor lung was
within 60min in all dogs. Through upper ab-
dominal laparotomy after lung transplanta-
tion, the omental pedicle was prepared for 
wrapping of bronchial anastomosis. 
 All recipient had plain chest roentogenograms 
perfomed every other days after trasplantation, 
and every days after 15 th p. o. d. 
 After fiberopic bronchoscope was performed 
befor and 7, 14, 21, days after operation, and 
pre and post pulse therapy. BALF was collcted 
through the channel of bronchoscope and pe-
ripheral blood was taken. la pasitive rate and 
RNA content of BALF and peripheral blood 
measureed. At the same time, open lung biopsy 
was performed. 
 Antibiotic ; AB-PC lgr was administered for 
7days after transplantation, and for 3days after 
open lung biopsy. 
2. Use of immunosuppressive drugs 
 Immunosuppressive regimen was admini-
stered orally every days from transplantation 
to death including sacrifice. 
transplantation'-7P. O. D. 
    CsA 20mg/kg/day 
    AZP 2.5mg/kg/day 
8P. O. D. ̂ -14P. O. D. 
    CsA 20mg/kg/day 
    AZP 2.5mg/kg/day 
    Pr 0.5mg/kg/day 
15P. O. D.-sacrificial day 
    CsA 10mg/kg/day 
    AZP 2.5mg/kg/day 
    Pr 0.5mg/kg/day 
 After day 15 CsA was reduced. Recipiant was 
treated with intraveous methylprednisolone, 
250mg/day daily for 3days when episodi of al-
lograft rejection was suspected by chest roent-
genograms. 
3. Collection of BALF 
 BALF was taken under general anesthesia 
through fiberoptic bronchoscope. After bron-
choscope was inserted until lobal bronchus of 
allograft, 30m1 saline at once was injected 
through channel of bronchoscope, and sucked 
until 100ml of recovery were obtained. 
4. Separation of mononuclear cell from periph-
eral blood and BALF 
 The samples of BALF filtrated three times 
with sponge, and periphral blood were putted 
up Ficoll-Conray fluid, adjusted to 1.077 specific
gravity and p.H 7.2, and centrifuged at 1700 rpm 
for 30min. Mononuclear cell alone was sepa-
rated, and floated in PBS. 
5. Measurement of la positive rate in lympho-
cytes and monocytes of periphral blood 
 10,ul of OKIa (Olth. Co.), as being primary 
antibody through 10,i1 of mouse IgG was ad-
ded to 200uil of peripheral blood and cultured 
at 4°C for 30min. Then as scondary antibody, 
additional 100ul of FITC, conjugated Goat 
antimouse IgG, was added, and cultured at 4°C 
for 30min. Only secondary antibody was added 
and cultured at 4'C for 30min for the negative 
control. After making hemolysis, 2ml of a 
medium 10%FCS-RPMI 1640 was added, and la 
positive rate was measured by Spectrum III 
(Flowcytometory, Olth. Co.). 
6. Measurement of la positive rate in lympho-
cytes and marcrophages of BALF 
 10,ul of OKIa antibody was added to 200,ul of 
BALF, that was adjusted to 5 X 106/ml, and 
cultured at 4°C for 30min, as same as peripheral 
blood. Then 100,ul of FITC conjugated Goat 
antimouse IgG, as secondary antibody, was 
added and cultured at 4°C for 30min. Only 
secondary antibody was added to 200,u1 of BALF 
and cultured at 4'C for 30min for the negative 
control. After this reaction, 2m1 of 10%FCS-
RPMI medium was added, and la positive rate 
measured by Spectrum III. 
7. Measurement of RNA content in monocytes 
of prephral blood and marcrophanges of BALF 
 2 X 106 mononuclear colls were fixed in ethanol-
aceton (ethtanol : aceton=l : 1), and stained with 
acridine orange". RNA content was measured 
by FACS IV (Flowcytometory Becton Dickinson. 
CO.). Fig. 1 represented DNA histogram and 
RNA histogram of BALF macrophages by FACS 
IV. RNA Peakchannel regaded as RNA content. 
8. Histologic evaluation of rejection 
 Any specimen of allograft, which was taken 
by open lung biopsy, were fixed in 10%formalin. 
Histologic examination of the lungs tissue was 
made by staining with Hematoxillin-Eosin for 
episod and degree of rejection. The degree of 
rejection was evaluated by Venth's classifica-
tions'. 
9. Analysis of data 
 All data were represtented by mean±standard 
deviation, and estimated by Wilcoxon test.
Fig. 1. DNA histogram and RNA histogram of BALF cell
          RESULT 
1) la-expression of lymphocytes in peripheral 
blood (Fig. 2) 
 The positive rate of la-expression of lym-
phocytes showed 61.0±13.7% (n=7) preopera-
tively. On day 7 after lung transplantation, 
under double therapy, CsA and AZP, it was 
72.6±14.2% in case without rejection and 71.4± 
13.3% in case with rejection, indicating a slight 
increase in positive rate of la-expression without 
statistically significant difference. 
 On the other hand, on day 14, it was 55.5± 
30.0% in case without rejection and 73.0±17.8% 
in case with rejection when used combination 
with pr. 
 Meanwhile, only the dosis of CsA was reduced 
on day 21, it was 70.0±4.7% in case without 
rejection and 76.8±10.4% in case with rejection. 
There was not significant differences between 
cases with and without rejection. 
2) la-expression of monocytes in peripheral 
blood (Fig. 3) 
 The positive rate of la-expression of mon-
ocytes in the peripheral blood was 35.4±10.0% 
prior to lung transplantation. On day 7, it was 
47.3±12.8% in case without rejection and 43.2± 
10.0% in case with rejection, showing the slight 
increase in the la-expression rate. In contrast,
on day 14, it was 40.3±24.4% in case without 
rejection and 46.7±4.6% in case with rejection, 
therefter, on day 21 it was 64.7±7.7% in case 
without rejection, and 46.5±7.7% in case with 
rejection indicating definite increase without 
significant variation. 
3) la-expression of lymphocytes in BALF (Fig. 
4) 
 The positive rate of la-expression of lym-
phocytes in BALF was 6.5±3.5% prior to lung
Fig. 2. la positive rate of peripheral blood lym-
      phocyte
Fig. 3. la positive rate of peripheral blood mono-
      cyte
transplantatiion. On day7 it increasedto30.5±3.0 
in case without rejection and 68.1±17.2% in case 
with rejection, showing statistically significant 
difference (p<0.05 and p<0.005) respectively. 
On day 14, it was 16.3±1.5% in case without 
rejection and 41.7±15.4% in case with rejection 
with elapse of 7 days when Prd was prescribed 
(p<0.02, and p<0.05). On day 21, it was 16.4± 
8.0 in case without rejection and 62.2±15.2% in 
case with rejection, showing significant increase 
in those with rejection. 
 There showed statistically significant differ-
ence (p<0.01) between cases with and without 
rejection in every measurement. 
 Fig. 5 showed a relationship between la-ex-
pression and rejection response. On day7, the 
positive rate of la-expression much more in-
creased in the group with severe rejection than 
with slight one. On the contraty, on dayl4, and 
21 much more decreased in severe one than in 
slight one without statistically significant dif-
ference. 
4) la-expression of macrophages in BALF (Fig. 
6) 
 The positive rate of Ia-expression was 62.3± 
25.6%. On day 7, it was 15.0±4.8% in case without 
rejection and 26.8±14.4% in case with rejection 
with statistical significance (p<0.025). On the 
other hand, on day 14, it was 82.6±14.7% in case
Fig. 4. la positive rate in BALF lymphocyte
without rejection and 47.1±23.5% in case with 
rejection, indicating recovery to the preopera-
tive values. On day 21, it was 63.5±2.5% in case 
without rejection and 52.3±15.0% in case with 
rejection, showing an increase as compared with 
those with positive cases, in contrast, a de-
creased as compared with those with negative 
cases. However, there was no definitive differ-
ence between with and without rejection. 
5) RNA content of monocytes in the peripheral 
blood (Fig. 7) 
 The RNA content of monocytes in the 
peripheral blood was 45±8.5. On day 7, it was 
47±12.1 in case without rejection, 53±11.3 with 
rejection, on day 14, 48±5.9 and 50.5±16.3, and 
on day 21 43±13.3 and 45±12.3, indicating not 
significant difference and not any difference 
between with and without rejection. 
6) RNA content of macrophages in BALF (Fig. 
8) 
 RNA content of macrohpages was 87±24.5 
prior to transplantation, on day 7, it was 77± 
21.9 in case without rejection and 53.810.9 in 
case with rejection, on day 14, 61±15.5 and 73.8± 
31.3 and also on day 21, 61±15.5 and 73.8±31.3 
and also on day 21, 61±2.8 and 38.3±5.8, 
demonstrating a decerase with time following 
lung transplantation without significant differ-
ence as well as not significant diference bet-
Fig. 5. la positive rate in BALF lymphocyte
Fig. 6. la positive rate in BALF macrophage Fig. 7. RNA content of peripheral blood monocyte
ween with and without rejection. 
7) Changes in la-expression by steroid pulse 
therapy (Fig. 9 ) 
 Histologic finding prior to prescription of 
steroid pulse therapy showed the slight degree 
of perivascular cuffing in two dogs and slight 
pneumonia in the remaining one. Following 
prescribing steroid pulse therapy, chest xp film 
showed elimination of infiltrative shadow and 
also disappearance of histologic findings, which
confirmed the appearance of rejection. 
 The positive rate of la-expression of macro-
phages in BALF and peripheral blood changed 
with a varying variety. In contrast, that of lym-
phocytes in BALF was reduced after completion 
of steroid pulse therapy.
       DISCUSSION 
It is well known that the outcome of organ
Fig. 8. RNA content in BALF macrophage
transplantation is closely related to antigenicity 
of major histocompatibility between a donor and 
a recipient. 
 Antigens of histocompatibility are classified 
into the two groups of class I and II according 
to functional characteristics, moleccular struc-
ture and genetic structure. 
 It is generally accepted that class I antigen 
widely distributes to all organs and cells. On 
the contray, la-antigen which is included in class 
II antigen is present in antigen - presenting
cells of B cells, a part of macrophanges and 
dendritic cells, immunocompetent cells includ-
ing a part of activated T cells, endothelial cells 
and parenchymal cells. 
 It is worthy of notice that la-expression is not 
only strong transplantation antigen but also 
plays a immunologically key role in recognition 
of mutural immunocompetent cells and interac-
tion of mixted lymphocyte reaction and cell 
mediated lymphocytolysis". 
 It is well known that rejection phenomenon 
is produced by recognition of antigenicity by 
phagocyting macrophages. 
 Antigens, which are phagocyted by macro-
phages, are diagested into lysosomes. These 
again appear on the surface of cell membrane 
of macrophages as the la-antigen complex, 
presenting antigen to helper T(TH) and syn-
thesize and generate interleukin 1(11_1)7 '. And 
so antigen-presented TH cells recognize la-anti-
gen and are activated by stimulation of IL-1. 
 As a result, activated TH cells generate IL-2, 
followed by generation of antibodies by B-cells, 
proliferating and differentiating precursor cyto-
toxic T lymphocytes (P-CTL) into CTL. P-CTL 
are activated by honologous antigens on the 
surface of target cells and cause damage to 
traget cells with help of CTL which is activated 
by IL-2". 
 Meanwhile, RNA synthesis which plays a key 
role in protein synthesis is enhanced at GI phase
Fig. 9. la positive rate of peripheral lymphocyte, monocytes, BALF lymphocytes and 
      BALF macrophage under the pulse therapy
of cell cycle". Most of lymphcytes and macro-
phages are present at Go phase. When these 
are activated by IL-1 and protein synthesis is 
initiated, transfering to G1 phase and activat-
ing RNA synthesis including m-RNA. In matter 
of fact, RNA content has become increased, 
reflecting the grade of cell activation. Acute 
rejection phenomenon following lung trans-
plantation is initiated by dotted findings of 
perivascular cuffing, followed by lung edema, 
fibrin depostion, alveolar bleeding and tissue 
necrosis10'. 
 Nakano2' reported that la-positive cells are 
present in the perivascular area at rejection and 
a presence of la-positive cells is inhibited by 
prescribing CsA. At present various immuno-
suppressive drugs are clinically used. However, 
CsA is of great value to improve the outcome 
of organ transplantation10' 11'. It is well known 
that CsA plays an important role in suppressing 
the immune response by inhibition of IL-1 
generation and in releasing it from macro-
phages"), IL-2 generation and release from 
activated T11131 and do damage to activation of 
CTL (generation of IL-2 and mRNA14') and also 
CsA is of great effect to inhibit RNA synthesis 
by macropahge, la expression by macrophages 
in BALF, lymphcytes and T-cell in the pe-
ripheral blood" 3, 15) 
 It is also accepted that Azp prevents DNA 
synthesis and directly caused damage to DNA 
synthesis in macrophages and T-cells, indi-
cating immunosuppressive effects"'. On the 
other hand, although the action of steroid upon 
depression of the immune response is not so 
clear, much research work has been detailed 
that IL-1 generation by macrophage17', IL-2 
generation by TH18), glucose and protein metab-
olism in lymphocytes 19) are uniformly inhibit-
ed. Meanwhile, many reports"" 5, 17, 11,21) certifies 
that la expression of macrophages and lym-
phocytes also is depressed. In this study, la 
expression was depressed with elapsed time of 
8 days following prescribing predonine. 
 In contrast, various kinds of immunosup-
pressive drugs have the side effects of nephro-
hepatotoxicity by CsA, bone marrow depression 
and hepatic dysfunction by Azp and delay in 
wound healing and disruption following infec-
tion at bronchial anastomosis by steroid22'.
Combination therapy of CsA, Azp and Pr is now 
prevalent. 
 In Toronto Lung Transplant Group"), com-
bination use of CsA and Azp is preoperatively 
applied and added anti-lymphocyte globuline in 
postoperative period. It is generally thought 
that one hesitate to use predonine until heiling 
of bronchial anastosis completes. In contrast, 
in case that rejection repeats on day 5 following 
allotransplantation, methylpredonine is used. 
 It is required that precise diagnosis of rejec-
tion should be done in early stage, identified 
it from infection. At present it is made by 
transbronchial, transcutaneous needle and/or 
open lung biopsies"'. Needless to say, open lung 
biopsy is the best way to precisely diagnose 
rejection"' although surgical insult is grave and 
frequent attempts are difficult to practically use. 
It is well known that the lung is directed 
outsides and has many chances to be affected 
by infectiion. BALT plays a significant role in 
defense mechanism against infection 15 ' and 
lymphocytes in BALT are replaced with 
lymphocytes from a recipient and provide a 
chance in close contact with antigens26'. It is 
suggested that intrabronchial BALF originated 
from protruded BALT is of great benefit to 
determine the apperance of rejection. Saito27' 
pointed out the fact that the ratio of lym-
phocytes to total cells in BALF increases 
according to occurrence of rejection and also the 
ratio of TH to non-helper T(Tn) decreases. 
Matsumura21) reported that the ratio of CD4 to 
CD' in lymphocytes of BALF decreases in the 
progression of rejection. Other reports clarifi-
ed that donor specific reactions to CML in 
lymphocytes of BALF and primed lympho-
cyte test are facilitated in accordance with 
progression of rejection 29) and active oxygen 
species production in macrophages of BALF 
was increased with pneumonia and rejection3o, 
The fact that RNA content in macrophages in 
BALF and monocytes in the peripheral blood 
falls down in the combination therapy is in-
dicating no valuable contribution to determina-
tion of the appearance of rejection phenomenon. 
It also indicates that there is no difference in 
la-expression between drugs used and the in-
tensity of rejection and also no significant con-
tribution to determination of rejection by the
examination of immunocompetent cells in the 
peripheral blood. 
 la-expression of BALF macrophages was sig-
nifcantly diminished at 7th day under therapy 
of CsA and AZP, and was recorved after used 
predonine togather. 
 A few days following lung allotransplanta-
tion accord with the time when macropahges 
recognize the histocompatibility antigen they 
activate phagocytic activity and dissolve into 
peptide at the time of la-negative period''. 
Therefore, one takes it into considereation that 
la-positive macrophages in BALF are very few. 
 On days 5 to 7 following lung allotransplan-
tation, macropahges exhibit antigen on the 
surface of cells as a la-antigen complex. On 
day 7 and later, it is easily thought la-positive 
macrophages have become increased. In this 
series, la expression of lymphocytes in BALF 
was inhibited by instillation of steroid and 
increased by occurrence of rejection. It did not 
vary greatly regardless of the slight or severe 
degress of rejection. It is concluded that the 
measurement of la expression is of great value 
to know the appearance of rejection.
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